Royal Fund Management LLC Purchases 20,625 Shares of Bristol Myers Squibb Company $BMY

Royal Fund Management LLC boosted its position in Bristol Myers Squibb Company (NYSE:BMY) by 51.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 60,467 shares of the biopharmaceutical company’s stock after buying an additional 20,625 shares during the quarter. Royal Fund Management LLC’s holdings in Bristol Myers Squibb were worth $3,261,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in Bristol Myers Squibb by 0.5% in the third quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock valued at $8,838,879,000 after purchasing an additional 1,058,803 shares in the last quarter. State Street Corp lifted its position in Bristol Myers Squibb by 2.0% during the 3rd quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company’s stock worth $4,356,445,000 after buying an additional 1,855,238 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Bristol Myers Squibb by 1.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock worth $1,508,099,000 after buying an additional 432,158 shares during the last quarter. Independent Franchise Partners LLP grew its holdings in shares of Bristol Myers Squibb by 20.6% in the 2nd quarter. Independent Franchise Partners LLP now owns 20,976,954 shares of the biopharmaceutical company’s stock valued at $971,023,000 after acquiring an additional 3,583,163 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Bristol Myers Squibb by 4.9% in the 2nd quarter. Invesco Ltd. now owns 18,315,473 shares of the biopharmaceutical company’s stock valued at $847,823,000 after acquiring an additional 852,317 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

BMY has been the topic of several analyst reports. Guggenheim reiterated a “buy” rating and set a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. The Goldman Sachs Group restated a “neutral” rating and issued a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Morgan Stanley reissued an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Finally, HSBC raised their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, March 17th. Nine analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus target price of $61.41.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Phase 3 SCOUT‑HCM data for Camzyos (mavacamten) in adolescents showed efficacy and safety, increasing the drug’s addressable market and raising the chance of label expansion and incremental sales for BMY’s cardiovascular franchise. Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT‑HCM Trial
• Positive Sentiment: The FDA granted approval for BMY’s combination regimen in Hodgkin’s lymphoma (announced March 20), adding a near‑term revenue stream and supporting sentiment around the oncology portfolio. Bristol‑Myers Squibb Gets FDA Approval for Hodgkin’s Lymphoma Treatment
• Neutral Sentiment: Phase 4 data for Cobenfy (xanomeline+tropium) presented safety/tolerability data in switching patients, which could reshape long‑term revenue assumptions if follow‑on studies or real‑world switching data are favorable — outcome still uncertain for valuation impact. Cobenfy Phase 4 Data May Reframe Bristol Myers Squibb Valuation Story
• Neutral Sentiment: Analyses highlight growth opportunities in the pancreatic adenocarcinoma market (projected high CAGR) where BMY is named among major players — long‑term tailwind but competitive landscape and timing of launches matter. Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR
• Neutral Sentiment: Several financial writeups point to BMY as an income/dividend name and note an upcoming ex‑dividend date; that can support demand from yield‑focused investors but doesn’t change fundamentals. Bristol‑Myers Squibb Looks Like A Good Stock, And It’s Going Ex‑Dividend Soon
• Negative Sentiment: Analyst coverage is mixed — roughly 60% of covering analysts have non‑bullish ratings even though the consensus price target implies limited upside, which could cap upside until guidance or earnings beat expectations and analysts raise targets. Bristol‑Myers Squibb Faces Mixed Analyst Sentiment

Bristol Myers Squibb Trading Up 2.1%

Bristol Myers Squibb stock opened at $59.76 on Tuesday. The stock has a 50-day simple moving average of $58.91 and a 200 day simple moving average of $52.35. The stock has a market capitalization of $122.01 billion, a P/E ratio of 17.32, a PEG ratio of 0.17 and a beta of 0.26. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the prior year, the company earned $1.67 EPS. Bristol Myers Squibb’s quarterly revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.